HIV Risk Reduction in Subutex Injectors in Tbilisi
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study will obtain pilot data on the acceptability of a 12-week course of daily observed
suboxone and methadone, followed by a dose taper or referral to a local treatment program for
80 opioid dependent patients (40 group) who have been injecting subutex or other
buprenorphine preparations 10 or more days in the past 30, and on the impact of each
medication on HIV risk and on subutex and opioid use during treatment and a followup at week
20. it will be done at the Uranti Methadone Program, affiliated with the Addiction Research
Center, Union Alternative of Georgia in Tbilisi.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Methadone Naloxone